VHIO brings breaking data to Stockholm: the 2011 European Multidisciplinary Cancer Congress

VHIO´s Director of Clinical Research and PI of the Gastrointestinal Tumours Group,  Josep Tabernero talks to ecancer Managing Editor Gordon McVie about the breaking research he presented at the 2011 European Multidisciplinary Cancer Conference, Stockholm, 23 – 27 September including results from VELOUR, a Phase III Study of Aflibercept (A) Versus Placebo (pbo) in Combination with FOLFIRI for the Treatment of Patients with Previously Treated Metastatic Colorectal Cancer (MCRC). FOL – folinic acid (leucovorin), F – fluorouracil (5-FU) and IRI – irinotecan.


Related Posts

Privacy Preferences
When you visit our website, it may store information through your browser from specific services, usually in form of cookies. Here you can change your privacy preferences. Please note that blocking some types of cookies may impact your experience on our website and the services we offer.